论文部分内容阅读
目的分析布地奈德联合特布他林雾化吸入治疗慢性支气管哮喘的临床疗效。方法选取2012年4月—2013年4月我院收治的慢性支气管哮喘患者110例,将其随机分为观察组和对照组,各55例。对照组采取常规基础治疗,观察组在对照组基础上采用布地奈德联合特布他林雾化吸入治疗,观察两组临床疗效。结果观察组总有效率为94.6%(52/55),高于对照组的72.4%(40/55)(P<0.05)。两组治疗后复发率比较,差异无统计学意义(P>0.05)。结论采用布地奈德联合特布他林雾化吸入治疗慢性支气管哮喘具有较好的疗效,患者治疗后复发率低,值得临床广泛运用。
Objective To analyze the clinical efficacy of budesonide combined with terbutaline in the treatment of chronic bronchial asthma. Methods A total of 110 patients with chronic bronchial asthma admitted to our hospital from April 2012 to April 2013 were selected and randomly divided into observation group and control group, each with 55 cases. The control group to take the conventional basic treatment, the observation group on the basis of the control group budesonide combined terbutaline nebulization treatment, the clinical efficacy of the two groups were observed. Results The total effective rate in the observation group was 94.6% (52/55), which was higher than that in the control group (72.4%, 40/55) (P <0.05). There was no significant difference in relapse rate between the two groups after treatment (P> 0.05). Conclusion The use of budesonide combined with terbutaline nebulization in the treatment of chronic bronchial asthma has a good effect, the recurrence rate of patients after treatment is low, it is widely used in clinical.